Current filters:


Popular Filters

8176 to 8200 of 8449 results

AstraZeneca gains rights to Heptares GPCR drug for $6.25 million upfront


Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that it has entered a four-year…

AstraZenecaDermatologicalsHeptares TherapeuticsLicensingNeurologicalPharmaceuticalResearch

Chiesi, Eli Lilly and Bayer named for breaches of the ABPI Code of Practice


The UK subsidiaries of Italy’s Chiesi, US drug major Eli Lilly (NYSE: LLY) and Germany’s Bayer…

BayerChiesi FarmaceuticiEli LillyEuropeLevitraNeurologicalPharmaceuticalRegulationReproductiveYasmin

Sanofi enters accord with DNDi to generate new drugs for neglected tropical diseases


French drug major Sanofi (Euronext: SAN) and Drugs for Neglected Diseases initiative (DNDi), a not-for-profit…

PharmaceuticalResearchSanofiTropical diseases

Roche joins forces with ChemRar on developing new antithrombotic drug for Russia


Swiss pharmaceutical major Roche (ROG: SIX) and Russian TeaReks company, a subsidiary of ChemRar, Roche's…

Cardio-vascularChemRar Hi-TechEuropeLicensingPharmaceuticalRocheTeaReks

German pharma hails progress against multiple sclerosis


Multiple sclerosis (MS) sufferers should soon have access to a range of drugs that offer better protection…

EuropeMarkets & MarketingNeurologicalPharmaceuticalResearch

US GPhA calls on House Appropriations Committee to protect funding for FDA; welcomes Solicitor General’s action


The USA’s Generic Pharmaceutical Association (GPhA) has written to House Appropriations Committee…

FinancialGenericsLegalNorth AmericaRegulation

Important implications of Abbott win in US patent ruling


US health care major Abbott Laboratories (NYSE: ABT) last week won a US appeals court ruling that will…

Abbott LaboratoriesLegalNorth AmericaPatentsPharmaceutical

Efficacy and stroke concerns halt trial of Abbott cholesterol drug Niaspan combo


US health care major Abbott Laboratories (NYSE ABT) has halted its AIM-HIGH clinical trial of Niaspan…

Abbott LaboratoriesCardio-vascularNiaspanPharmaceuticalResearchSimvastatin

Canada’s Quebec Province overhauls cancer drug evaluation


The Canadian Province of Quebec, which has the highest incidence of new cancer cases in the country,…

North AmericaPharmaceuticalRegulation

German approval for GW and Almirall’s Sativex for spasticity due to MS


Spain’s leading drugmaker Almirall (ALM) and UK-based originator of the cannabis based product GW…

AlmirallEuropeGW PharmaceuticalsNeurologicalPharmaceuticalRegulationSativex

HAI Europe injects public health perspective into European Research and Innovation Framework


Consumer group Health Action International (HAI) Europe has submitted a response to the European Commission…


Two more product approvals in Russia for India’s Claris


Claris Lifesciences (CLAR: IN), one of the largest sterile injectables pharmaceutical companies in India,…

Antibiotics and Infectious diseasesClaris LifesciencesEuropeFluconazoleGenericsLevofloxacinRegulation

Major stakeholders optimistic about future of drug development, but differ on defining value


Biopharmaceutical executives, managed care executives, physicians and patients with chronic illness foresee…

HealthcareNorth AmericaPharmaceuticalResearch

Synovate Healthcare launches Hyperlipidemia Monitor in Asia-Pacific


Synovate Healthcare, the health care specialist unit of market research firm Synovate, says it has launched…


US Senators accuse Sanofi over lobbying FDA on generic Lovenox


US Senate Finance Committee Chairman Max Baucus (Democrat, Montana) and senior Committee Member Chuck…

Cardio-vascularGenericsLovenoxNorth AmericaPharmaceuticalRegulationSanofi

Patient access and industry competitiveness at stake in EU Transparency Directive review, says EFPIA


With the review of the European Union’s Transparency Directive (Directive 89/105/EEC) gaining momentum,…


Emerging markets continue to drive Nycomed in first quarter 2011


Independent Swiss drugmaker Nycomed, which is the subject of an agreed 9.6 billion-euro takeover by Japan’s…


Vaccine side effects under the microscope in Australia


Australia’s Gillard government yesterday released an independent assessment of the nation's management…


UK’s NICE recommends naftidrofuryl oxalate for symptoms of peripheral arterial disease


The National Institute for Health and Clinical Excellence (NICE) has today issued final guidance recommending…

Cardio-vascularEuropeMerck SerononaftidrofurylPharmaceuticalPraxilenePricingRegulation

8176 to 8200 of 8449 results

Back to top